TOPICS
Content Calendar for Biotech & Pharma
DIRECT ANSWER
A content calendar is a forward-looking schedule that maps every planned content asset — blog posts, social updates, email campaigns, videos — to a publish date, channel, owner, and target audience. It coordinates production across teams, prevents coverage gaps, and ensures content aligns with business events, campaigns, and seasonal demand. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What content calendar means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
What a content calendar should contain
An effective content calendar captures more than publish dates. Each entry should include: content type and format, target keyword or audience segment, assigned owner, draft-due and publish dates, distribution channels, CTA and funnel stage, and a status field (planned, in-review, scheduled, live). Teams that track funnel stage per asset are better positioned to spot imbalances — most content calendars skew heavily toward top-of-funnel awareness content and underserve mid-funnel decision content.
Research from Content Marketing Institute indicates that teams with a documented content calendar are 3x more likely to report effective content programs than those working ad hoc. Calendar cadence varies widely: B2B SaaS companies typically publish 4–12 blog posts per month; enterprise brands running full-funnel programs may schedule 50–200 assets across channels in a given week.
Running content calendar for Biotech & Pharma with CoMo
CoMo's agents apply content calendar across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Content Calendar for Biotech & Pharma — common questions
What tool should I use for a content calendar?
For teams under five, a shared spreadsheet or Notion database is sufficient. Teams managing multiple channels and contributors benefit from a dedicated tool (Airtable, CoSchedule, Asana) that supports workflow states and channel views. The tool matters less than the data fields: if each entry lacks a funnel stage, target keyword, and owner, the calendar is a schedule, not a strategy.
How does content calendar differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.